StoxSun Pharmaceutical Industries vs Laurus Labs: share price & financials comparison
NSE: SUNPHARMA vs LAURUSLABS · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Sun Pharmaceutical Industries vs Laurus Labs at a glance
Sun Pharmaceutical Industries (SUNPHARMA) has a market capitalisation of ₹4,46,270 Cr, against ₹1,26,430 Cr for Laurus Labs (LAURUSLABS). Over the past year Laurus Labs has returned +143.3%, compared with +8.4% for Sun Pharmaceutical Industries. On valuation, Sun Pharmaceutical Industries trades at a lower P/E of 40.7 versus 94.4. Laurus Labs earns a higher return on equity (22.1% vs 12.3%). Sun Pharmaceutical Industries comes out ahead on size, valuation and financial health. Laurus Labs comes out ahead on profitability, growth, momentum and technicals. Across the scored metrics below, Sun Pharmaceutical Industries leads on 7 and Laurus Labs on 10. On StoxGud's 10-point checklist, Sun Pharmaceutical Industries scores 8/10 and Laurus Labs scores 8/10.
| Metric | Sun Pharmaceutical Industries | Laurus Labs |
|---|---|---|
| Size | ||
| Market cap | ₹4,46,270 Cr | ₹1,26,430 Cr |
| Revenue (latest FY) | ₹58,462 Cr | ₹6,813 Cr |
| Net profit (latest FY) | ₹11,479 Cr | ₹889 Cr |
| Valuation | ||
| P/E | 40.7 | 94.4 |
| P/B | 5.00 | 20.86 |
| Dividend yield | 0.88% | 0.07% |
| Profitability | ||
| Return on equity | 12.3% | 22.1% |
| Net profit margin | 17.8% | 17.1% |
| Operating margin | 29.3% | 30.4% |
| Growth | ||
| Revenue growth (YoY) | +11.9% | +33.4% |
| Net profit growth (YoY) | -36.2% | +126.4% |
| Revenue CAGR (multi-year) | +11.8% | +7.2% |
| Financial health | ||
| Debt to equity | 0.03 | 0.41 |
| Momentum | ||
| 1-month return | +4.4% | +14.0% |
| 1-year return | +8.4% | +143.3% |
| 3-year CAGR | +17.4% | +84.5% |
| 5-year CAGR | +18.4% | +36.4% |
| 10-year CAGR | +11.0% | — |
| Distance from 52W high | -7.1% | -2.7% |
| Technicals | ||
| RSI (14) | 77 | 71 |
| Price vs 200-day avg | +2.7% | +58.0% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Sun Pharmaceutical Industries | Laurus Labs |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 8/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Sun Pharmaceutical Industries or Laurus Labs?
Sun Pharmaceutical Industries has a market cap of ₹4,46,270 Cr and Laurus Labs has a market cap of ₹1,26,430 Cr as of 06 Nov 2026.
Which has a lower P/E, Sun Pharmaceutical Industries or Laurus Labs?
Sun Pharmaceutical Industries has the lower P/E: Sun Pharmaceutical Industries trades at 40.7 and Laurus Labs at 94.4.
Which gave better returns in the last year, Sun Pharmaceutical Industries or Laurus Labs?
Laurus Labs did better: Sun Pharmaceutical Industries returned +8.4% and Laurus Labs returned +143.3% over one year.
Is Sun Pharmaceutical Industries or Laurus Labs a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Sun Pharmaceutical Industries scores 8/10 and Laurus Labs scores 8/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.